Hepatotoxic Interaction of Sulindac with Lipopolysaccharide: Role of the Hemostatic System
Open Access
- 12 December 2008
- journal article
- research article
- Published by Oxford University Press (OUP) in Toxicological Sciences
- Vol. 108 (1), 184-193
- https://doi.org/10.1093/toxsci/kfn259
Abstract
Sulindac (SLD) is a nonsteroidal anti-inflammatory drug (NSAID) that has been associated with a greater incidence of idiosyncratic hepatotoxicity in human patients than other NSAIDs. One hypothesis regarding idiosyncratic adverse drug reactions is that interaction of a drug with a modest inflammatory episode precipitates liver injury. In this study, we tested the hypothesis that lipopolysaccharide (LPS) interacts with SLD to cause liver injury in rats. SLD (50 mg/kg) or its vehicle was administered to rats by gavage 15.5 h before LPS (8.3 × 105 endotoxin unit/kg) or its saline vehicle (i.v.). Thirty minutes after LPS treatment, SLD or vehicle administration was repeated. Rats were killed at various times after treatment, and serum, plasma, and liver samples were taken. Neither SLD nor LPS alone caused liver injury. Cotreatment with SLD/LPS led to increases in serum biomarkers of both hepatocellular injury and cholestasis. Histological evidence of liver damage was found only after SLD/LPS cotreatment. As a result of activation of hemostasis induced by SLD/LPS cotreatment, fibrin and hypoxia were present in liver tissue before the onset of hepatotoxicity. Heparin treatment reduced hepatic fibrin deposition and hypoxia and protected against liver injury induced by SLD/LPS cotreatment. These results indicate that cotreatment with nontoxic doses of LPS and SLD causes liver injury in rats, and this could serve as a model of human idiosyncratic liver injury. The hemostatic system is activated by SLD/LPS cotreatment and plays an important role in the development of SLD/LPS-induced liver injury.Keywords
This publication has 41 references indexed in Scilit:
- p38 Mitogen-Activated Protein Kinase-Dependent Tumor Necrosis Factor-α-Converting Enzyme Is Important for Liver Injury in Hepatotoxic Interaction between Lipopolysaccharide and RanitidineJournal of Pharmacology and Experimental Therapeutics, 2008
- Lipopolysaccharide and Trovafloxacin Coexposure in Mice Causes Idiosyncrasy-Like Liver Injury Dependent on Tumor Necrosis Factor-AlphaToxicological Sciences, 2007
- The Role of Tumor Necrosis Factor Alpha in Lipopolysaccharide/Ranitidine-Induced Inflammatory Liver InjuryToxicological Sciences, 2007
- Modest Inflammation Enhances Diclofenac Hepatotoxicity in Rats: Role of Neutrophils and Bacterial TranslocationJournal of Pharmacology and Experimental Therapeutics, 2006
- Adverse hepatic drug reactions: inflammatory episodes as consequence and contributorChemico-Biological Interactions, 2004
- Modes of Cell Death in Rat Liver after Monocrotaline ExposureToxicological Sciences, 2003
- Ranitidine Treatment during a Modest Inflammatory Response Precipitates Idiosyncrasy-Like Liver Injury in RatsJournal of Pharmacology and Experimental Therapeutics, 2003
- Mechanisms of NSAID-Induced HepatotoxicityDrug Safety, 2002
- Clearance of argininosuccinate synthetase from the circulation in acute liver diseaseClinical Biochemistry, 1990
- Metabolism in vitro of sulindac. Sulfoxide-reducing enzyme systems in guinea pig liver.Journal of Pharmacobio-Dynamics, 1980